524 related articles for article (PubMed ID: 28919551)
21. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes.
Commander NJ; Spencer SA; Wren BW; MacMillan AP
Vaccine; 2007 Jan; 25(1):43-54. PubMed ID: 17049676
[TBL] [Abstract][Full Text] [Related]
22. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.
Abkar M; Lotfi AS; Amani J; Eskandari K; Ramandi MF; Salimian J; Brujeni GN; Alamian S; Kamali M; Koushki H
Vet Res Commun; 2015 Dec; 39(4):217-28. PubMed ID: 26395469
[TBL] [Abstract][Full Text] [Related]
23. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep.
Wang W; Wu J; Qiao J; Weng Y; Zhang H; Liao Q; Qiu J; Chen C; Allain JP; Li C
Vaccine; 2014 Feb; 32(7):825-33. PubMed ID: 24370708
[TBL] [Abstract][Full Text] [Related]
25. Oral immunization of mice with Omp31-loaded
Abkar M; Fasihi-Ramandi M; Kooshki H; Sahebghadam Lotfi A
Int J Nanomedicine; 2017; 12():8769-8778. PubMed ID: 29263667
[TBL] [Abstract][Full Text] [Related]
26. In Silico Prediction of a Multitope Vaccine against
Soltan MA; Elbassiouny N; Gamal H; Elkaeed EB; Eid RA; Eldeen MA; Al-Karmalawy AA
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34207238
[No Abstract] [Full Text] [Related]
27. Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches.
Nezafat N; Eslami M; Negahdaripour M; Rahbar MR; Ghasemi Y
Mol Biosyst; 2017 Mar; 13(4):699-713. PubMed ID: 28194462
[TBL] [Abstract][Full Text] [Related]
28. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice.
Golshani M; Rafati S; Dashti A; Gholami E; Siadat SD; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Jun; 65(2):287-92. PubMed ID: 25723468
[TBL] [Abstract][Full Text] [Related]
30. Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.
Zai X; Yin Y; Guo F; Yang Q; Li R; Li Y; Zhang J; Xu J; Chen W
Vet Res; 2021 Jun; 52(1):75. PubMed ID: 34078437
[TBL] [Abstract][Full Text] [Related]
31. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
Mailybayeva A; Yespembetov B; Ryskeldinova S; Zinina N; Sansyzbay A; Renukaradhya GJ; Petrovsky N; Tabynov K
PLoS One; 2017; 12(10):e0186484. PubMed ID: 29023541
[TBL] [Abstract][Full Text] [Related]
32. Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.
Gomez G; Pei J; Mwangi W; Adams LG; Rice-Ficht A; Ficht TA
PLoS One; 2013; 8(3):e59751. PubMed ID: 23533646
[TBL] [Abstract][Full Text] [Related]
33. A comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of Brucella melitensis Omp31.
Abkar M; Alamian S; Sattarahmady N
Immunol Lett; 2019 Mar; 207():28-35. PubMed ID: 30707922
[TBL] [Abstract][Full Text] [Related]
34. Novel multi-epitope vaccine against bovine brucellosis: approach from immunoinformatics to expression.
Rahimnahal S; Yousefizadeh S; Mohammadi Y
J Biomol Struct Dyn; 2023; 41(24):15460-15484. PubMed ID: 36927475
[TBL] [Abstract][Full Text] [Related]
35. Design of a multi-epitope vaccine candidate against Brucella melitensis.
Li M; Zhu Y; Niu C; Xie X; Haimiti G; Guo W; Yu M; Chen Z; Ding J; Zhang F
Sci Rep; 2022 Jun; 12(1):10146. PubMed ID: 35710873
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
Al-Mariri A; Abbady AQ
J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
[TBL] [Abstract][Full Text] [Related]
37. Design and Production of a Novel Recombinant Chimeric IL2-Omp31 Antigen against Brucella Infection.
Naghavi M; Sekhavati MH; Tahmoorespur M; Nassiri MR
Arch Razi Inst; 2018 Sep; 73(3):199-206. PubMed ID: 30280839
[TBL] [Abstract][Full Text] [Related]
38. Pangenome and immuno-proteomics analysis of Acinetobacter baumannii strains revealed the core peptide vaccine targets.
Hassan A; Naz A; Obaid A; Paracha RZ; Naz K; Awan FM; Muhmmad SA; Janjua HA; Ahmad J; Ali A
BMC Genomics; 2016 Sep; 17(1):732. PubMed ID: 27634541
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticle-Based Vaccines for Brucellosis: Calcium Phosphate Nanoparticles-Adsorbed Antigens Induce Cross Protective Response in Mice.
Sadeghi Z; Fasihi-Ramandi M; Bouzari S
Int J Nanomedicine; 2020; 15():3877-3886. PubMed ID: 32581535
[TBL] [Abstract][Full Text] [Related]
40. Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing
Bugybayeva D; Ryskeldinova S; Zinina N; Sarmykova M; Assanzhanova N; Kydyrbayev Z; Tabynov K
Biomed Res Int; 2020; 2020():1438928. PubMed ID: 33274194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
